9th Conference Resources



9th International Conference on Typhoid and Invasive NTS Disease


*Some presentations have been excluded at the request of the presenter

May 1st

Surveillance for Enteric Fever in Asia Project

Kashmira Date, US Centers for Disease Control and Prevention

Case control study to identify risk factors for typhoid fever in Central Division, Fiji – Preliminary results

Namrata Prasad, University of Otago, New Zealand

Environmental, socio-cultural, and behavioral determinants of typhoid fever in the Central Division, Republic of Fiji: an interdisciplinary investigation at multiple scales

Aaron Jenkins, Edith Cowan University, Australia

Demographic and Clinical Characteristics of Adult Patients with Typhoid Fever in Cipto Mangunkusumo General Hospital Jakarta Indonesia in 2012-2014

Bonita Effendi, Universitas Indonesia, Indonesia

Mathematical modeling reveals the potential consequences of the worldwide emergence of the H58 haplotype of Salmonella Typhi

Virginia Pitzer, Yale School of Public Health, United States

Modelling the contributions of malaria, HIV, and malnutrition to a decline in paediatric invasive non-typhoidal Salmonella disease, Malawi

Melita Gordon, University of Liverpool, United Kingdom

Evaluation of a rapid real-time molecular assay to identify S. Typhi, S. Paratyphi A and S. spp from suspected typhoid blood specimen in Bangladesh

Jean-Noël Telles, Fondation Mérieux, France

Typhoid fever in Bangladesh: from infection to protection

Firdausi Qadri, icddr,b, Bangladesh

High rates of enteric fever diagnosis and low burden of disease in rural Nepal

Jason Andrews, Stanford University, United States

Linking typhoid transmission to the water distribution system in Katmandu, Nepal

Stephen Baker, Oxford University Clinical Research Unit, Viet Nam

Impact of a water quality intervention on typhoid incidence in urban India

Ayse Ercumen, University of California Berkeley, United States

The current state of Salmonella research: successes, challenges, barriers, research gaps

Gordon Dougan, Wellcome Trust Sanger Institute, United Kingdom


May 2nd

Data from Nigeria: hospitalizations and complications

Stephan Obaro, The University of Nebraska Medical Center, United States

Epidemiological data from Africa: case fatality and association with drug resistance

Jan Jacobs, Institute of Tropical Medicine, Belgium

Data from Malawi: outbreak data and factors related to complications

Nicholas Feasey, Liverpool School of Tropical Medicine, United Kingdom

Cost of Illness Due to Typhoid Fever in Pemba, Zanzibar, East Africa

Arthorn Riewpaiboon, Mahidol University, Thailand

In-vitro resistance of Salmonella Typhi and Paratyphi A raises concern on the use of older fluroquinolones as the first line therapy

Palpasa Kansakar, WHO-Nepal, National Public Health Library, Nepal

Clinically and microbiologically derived azithromycin susceptibility breakpoints for Salmonella enterica serovars Typhi and Paratyphi A

Christopher Parry, London School of Hygiene and Tropical Medicine, United Kingdom

Evolving susceptibility patterns in invasive Salmonella typhi isolates in South Africa during 2003 to 2014

Arvinda Sooka, National Institute for Communicable Diseases, South Africa

HLA and resistance to enteric fever

Sarah Dunstan, The University of Melbourne, Australia

Immunity to invasive Salmonella infections: lessons from animal models and man

Pietro Mastroeni, University of Cambridge, United Kingdom

Salmonella Typhi host specificity: new insights from the study of Typhoid toxin

Jorge E. Galán, Yale University School of Medicine, United States

Understanding NTS transmission

Karen Keddy, National Institute for Communicable Diseases, South Africa

iNTS burden in sub-Saharan African children: an African view

Simon Kariuki, KEMRI-CDC, Kenya

Dissecting immune responses against iNTS

Tonney Nyirenda, Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Malawi

Requirements for tackling NTS disease

Allan Saul, Vaccines Institute for Global Health, A GSK company, Italy

The growing burden of S. Paratyphi A in Kathmandu: epidemiological observations from a decade of clinical trials

Corinne Thompson, Oxford University Clinical Research Unit, Viet Nam

Development of a Human Model of Salmonella enterica serovar Paratyphi A challenge in Healthy Adult Volunteers.

Hazel Dobinson, Oxford Vaccine Group, Oxford University, United Kingdom

The current status of vaccine development for control of Salmonella Paratyphi A

Rodney Carbis, International Vaccine Institute, Republic of Korea

Salmonella enterica serotype Paratyphi A: Common cause of Salmonelloses among patients attending Om Hospital and Research Centre, Kathmandu, Nepal

Ram Krishna Shrestha, Om Hospital and Research Center, Nepal


May 3rd

Typhoid vaccine Introduction in Nepal

YV Pradhan, Society of Public Health Physicians, Nepal (SOPHYN)

Typhoid vaccination in Sri Lanka

Dr. Paba Palihawadana, Ministry of Health, Sri Lanka

Integration of typhoid conjugate vaccine in national immunization schedules: Opportunities and Challenges

Krishna Mohan, Bharat Biotech International Limited, India

New Vaccine Introduction Decision Making: Principles, Practices, and Realities

Michael Friedman, World Health Organization, Indonesia

Typbar TCV™ – A Vi polysaccharide-Tetanus Toxoid conjugate vaccine: Safety and immunogenicity in healthy infants, children and adults in typhoid endemic areas.

Vineeth Varanasi, Bharat Biotech International, Limited, India

Progress in the development of a Vi-DT conjugate vaccine

Erman Tritama, Bio Farma, Indonesia

Progress in the development of a Vi-CRM197 conjugate vaccine

Akshay Goel, Biological E, India